With the reshuffle of the CEO, CTO and CFO roles, I wonder if we have a consensus on the true meaning of the changes?
I note the following from Doug Wilson in BioSpectrum:
"Dr Wilson noted the company management structure had been reorganized to position it for the on-going contractual obligations and emerging strategic opportunities".
I am reminded of the quotes at the time of the appointment of Griffin Securities:
Mr Stecyk said that, "We look forward to exploring the variety of strategic options that could significantly build shareholder value including: broad therapeutic discovery alliances; partnerships spanning other applications of the platform such as animal health, agriculture and industrial; and, strategic opportunities with companies with synergistic technology."
There must be some interesting perspectives on all of this.
PYC Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)